Skip to content

Science & applications

Hair enhancement science.

Explore cosmetic peptides, prostaglandin analogs, mechanism research and formulation context.

Biotinoyl Tripeptide-1 molecular structure.
Molecular identity

Where these actives fit

Comparative positioning

Mironova offers cosmetic peptide and prostaglandin pathways for hair enhancement. Below is where these product families offer specific advantages and where they differ from established options.

Application-specific comparisons. Product suitability depends on the formulation and market.
ScenarioIncumbentKnown limitationMironova advantageRecommended
Lash/Brow Peptide Actives

Cosmetic peptide ingredients for eyelash and eyebrow enhancement serums

Redensyl, Capixyl (Acetyl Tetrapeptide-3), generic peptide blendsMany marketed lash peptide blends lack ingredient-specific data. Capixyl data cannot be attributed to Biotinoyl Tripeptide-1 (different peptide). Evidence quality varies widely across suppliers.Mironova supplies four cosmetic peptides with clearly graded evidence levels: Biotinoyl Tripeptide-1 (strongest evidence, supplier ex vivo data) and three Myristoyl lipopeptides for keratin support and multi-peptide formulations. Evidence grades are disclosed transparently. [P1], [P2]Myristoyl Pentapeptide-17 + Hexapeptide-16
Matrikine / ECM Support

Targeting extracellular matrix remodeling in the follicular environment

GHK-Cu (copper peptide), Procapil (3-ingredient complex)GHK-Cu is a well-characterized ECM modulator, but its copper coordination raises formulation complexity and stability challenges. Procapil clinical data tests the full complex, not the peptide component alone.Biotinoyl Tripeptide-1 preserves laminin-5 and collagen IV in the dermal papilla and root sheath (supplier ex vivo data). Copper-free GHK conjugate simplifies formulation. Follicular localization demonstrated by immunolabeling. [P3], [P4]Biotinoyl Tripeptide-1
Maximum Efficacy Lash/Brow Enhancement

Formulations prioritizing rapid growth phase extension in permissive regulatory markets

Cosmetic peptides & botanical extractsWhile peptides offer excellent regulatory safety, their clinical efficacy rarely matches the visible, rapid growth phase extension driven by prostaglandin receptor pathways.Mironova supplies >15 high-purity prostaglandin analogs (Bimatoprost, Latanoprost, etc.) with full analytical characterization for brands operating in permissive regulatory markets prioritizing maximum efficacy. Bimatoprost or Latanoprost

Mechanism of action

Three mechanistic pathways across two active families

Each pathway is presented with an evidence confidence rating. We distinguish between what the literature directly supports and what remains a plausible hypothesis.

Cosmetic Peptides

GHK matrikine signaling and myristoylated lipopeptides for ECM remodeling and keratin support.

GHK Matrikine Signaling & ECM Remodeling

GHK is a naturally occurring human plasma tripeptide that functions as a matrikine — a bioactive ECM-derived signaling fragment. Connectivity Map analysis indicates GHK modulates expression of over 4,000 human genes, including ECM synthesis, growth factor, anti-inflammatory, and stem cell pathways. Biotinoyl Tripeptide-1 is a biotin-conjugated derivative designed for improved stability and follicular delivery.

Active ingredient
GHK / Biotinoyl Tripeptide-1 (Biotin-GHK)
Product
Biotinoyl Tripeptide-1
Evidence confidence
Medium

Scope of the evidence

Strong evidence for the GHK parent peptide (five decades of research, multiple independent groups, CIR safety review). However, Biotinoyl Tripeptide-1 specifically has no independent peer-reviewed efficacy data — all evidence comes from Sederma’s proprietary technical files or multi-ingredient formulation studies. The biotin conjugate’s efficacy relies on the reasonable but unvalidated assumption that the GHK sequence retains signaling properties when copper coordination is replaced by biotin.

Mechanistic detail
  • GHK is a naturally occurring human plasma tripeptide first described in the early 1970s. Reported plasma concentrations decline with age, correlating with declining regenerative capacity [B25].
  • GHK complexes with copper (II) ions with exceptionally high affinity (log K = 16.44), forming GHK-Cu. The complex is maximally bioactive, serving both as a gene-modulating matrikine and a safe copper delivery vector [B25].
  • Connectivity Map data (Pickart & Margolina, 2018) indicates GHK modulates genes for ECM synthesis (collagen I/III, decorin), growth factors (VEGF, bFGF — up to 230% increase), anti-inflammatory pathways (NF-κB, TNF-α suppression), and stem cell maintenance (57 stem cell genes upregulated ≥50%). These findings were independently validated by Campbell et al. (2012) at Boston University [B26].
  • Sederma’s ex vivo follicle culture data shows Biotinoyl Tripeptide-1 at 2 ppm increased follicular growth by 58% vs controls, comparable to minoxidil. At 5 ppm, growth was 121% greater than controls. This data is supplier-generated and has not been independently replicated.
  • The biotin conjugation enhances stability (no copper-related oxidation or color), improves cosmetic compatibility, and may enhance follicular substantivity. However, it reduces the peptide’s copper-binding affinity, shifting the mechanism from copper delivery toward pure matrikine signaling.
  • The widely cited claim that biotin “anchors” the peptide to fibronectin/laminin via avidin-like binding is not supported by evidence. The enhanced ECM integration observed clinically is attributable to GHK-mediated gene signaling that upregulates ECM protein synthesis, not a direct biochemical binding mechanism.
Evidence gaps
  • No independent peer-reviewed study tests Biotinoyl Tripeptide-1 as a monotherapy
  • Clinical studies (Procapil) test a three-ingredient complex; individual contribution of the peptide cannot be isolated
  • Pyo et al. (2007) — the most-cited hair follicle study — tested AHK-Cu (Ala-His-Lys), not GHK-Cu; these are structurally related but distinct
  • No direct GHK-Cu monotherapy RCT for hair loss in humans
  • Biotin-ECM “anchoring” mechanism is a marketing claim unsupported by physiological evidence

Myristoyl Lipopeptide Keratinocyte Support

Three myristoylated (C14) cosmetic lipopeptides designed for enhanced cutaneous penetration and targeted follicular activity. Originating from eyelash growth applications (Symrise SymPeptide® line), these peptides are increasingly used in scalp and brow formulations. The evidence base is primarily supplier-generated in vitro data; independent peer-reviewed validation as standalone actives is absent.

Active ingredient
Myristoyl Pentapeptide-17 / Hexapeptide-16 / Tetrapeptide-12
Product
Myristoyl Lipopeptide Portfolio
Evidence confidence
Low

Scope of the evidence

No independent peer-reviewed clinical or in vitro data exists for any of the three myristoyl lipopeptides as standalone ingredients. All efficacy data is supplier-generated (Symrise for Pentapeptide-17 and Hexapeptide-16; Jan Marini for Tetrapeptide-12). Eyelash efficacy data cannot be directly extrapolated to scalp hair due to different hormonal sensitivity and lifecycle duration. Several widely circulated mechanism claims (KRT31/KRT35 for MP-17, Wnt modulation for MH-16) cannot be traced to primary data sources.

Mechanistic detail
  • Myristoylation conjugates a C14 saturated fatty acid to the peptide N-terminus, significantly increasing lipophilicity and enabling the molecule to partition into the lipid-rich follicular environment. This is a well-established peptide delivery strategy in cosmetic chemistry.
  • Myristoyl Pentapeptide-17 (Myr-KLAKK-NH₂): Symrise supplier data shows 80–160% upregulation of keratin genes (KRT3, KRT19, lumican) in EpDermFT™ human skin model. A supplier hair loss study (n=24, 90 days) showed a telogen decrease trend that did not reach statistical significance (p=0.148).
  • Myristoyl Hexapeptide-16 (Myr-LKKALK): Almost exclusively studied alongside Pentapeptide-17. No independent published data exists for this peptide as a single active. Claims of Wnt/β-catenin modulation and stem cell niche support are hypothetical — no biochemical assays connect this specific peptide to those pathways.
  • Myristoyl Tetrapeptide-12 (Myr-KAKA): Originated by Jan Marini Skin Research. Supplier data indicates ECM protein upregulation (collagen IV, fibronectin). The claimed SMAD2/3 activation mechanism presents a biological paradox — classical TGF-β/SMAD signaling in follicular biology is associated with catagen induction, not anagen promotion.
Evidence gaps
  • No independent peer-reviewed study tests any of the three myristoyl lipopeptides as a single active ingredient
  • KRT31/KRT35 upregulation claim for Myristoyl Pentapeptide-17 cannot be traced to primary data; Symrise microarray shows KRT3/KRT19/LUM instead
  • Wnt/β-catenin modulation and HFSC niche support claims for Myristoyl Hexapeptide-16 have no published biochemical evidence
  • SMAD2/3 mechanism for Myristoyl Tetrapeptide-12 contradicts classical TGF-β follicular biology (catagen-inducing, not anagen-promoting)
  • No scalp-specific trichoscopy or trichogram studies for any of the three peptides
  • Eyelash efficacy (short 30–45 day cycle, no DHT sensitivity) may not translate to scalp (2–6 year anagen, DHT-driven miniaturization)

Prostaglandin Analogs

FP receptor-mediated anagen prolongation with FDA-approved clinical precedent.

FP Receptor Agonism & Anagen Prolongation

Prostaglandin F2α analogs activate the prostanoid FP receptor on dermal papilla cells, prolonging anagen phase duration and increasing the proportion of follicles in active growth. This is the best-evidenced pharmacological pathway for eyelash and eyebrow enhancement, with FDA-approved precedent (bimatoprost ophthalmic solution 0.03%).

Active ingredient
Bimatoprost, Latanoprost, Travoprost & Analogs
Product
Prostaglandin Analog Portfolio
Evidence confidence
High

Scope of the evidence

FDA-approved indication (bimatoprost for eyelash hypotrichosis) with Phase III RCT data. Multiple independent clinical studies support the anagen-prolonging mechanism. Class-level FP receptor pharmacology is well characterized. Scalp hair applications have emerging but limited clinical evidence.

Mechanistic detail
  • Bimatoprost (Latisse®) is FDA-approved for hypotrichosis of the eyelashes. Clinical trials demonstrated statistically significant increases in lash length (+25%), thickness (+106%), and darkness (+18%) over 16 weeks vs placebo.
  • The mechanism involves FP receptor-mediated signaling in the dermal papilla, which prolongs the anagen growth phase and may recruit telogen follicles into a new anagen cycle. Prostaglandin analogs also increase melanogenesis, contributing to the darkening effect.
  • Latanoprost acid has been studied as a topical treatment for androgenetic alopecia in small pilot trials. Blume-Peytavi et al. (2012) reported increased hair density and terminal-to-vellus hair ratio in a 24-week RCT using 0.1% latanoprost solution.
  • Prostaglandin analogs represent a distinct pharmacological class from the non-prostaglandin actives on this page. They carry a different risk profile including potential periorbital fat atrophy (PAP), iris pigmentation changes, and regulatory classification as drugs in some jurisdictions.
  • Mironova manufactures a comprehensive portfolio of prostaglandin analogs including bimatoprost (free acid and ester forms), latanoprost, travoprost, cloprostenol, tafluprost, and fluprostenol at ≥98% purity.
Evidence gaps
  • Scalp AGA indication not FDA-approved for any prostaglandin analog
  • Long-term safety of topical scalp prostaglandin application not established in large RCTs
  • Periorbital adverse effects (fat atrophy, pigmentation) documented with ophthalmic use; scalp-specific safety profile less characterized
  • Optimal concentration and formulation for scalp applications not yet standardized

Published evidence

What the literature supports

The information on this page references published research where available. We rate each finding by evidence quality and explicitly note limitations — because transparent science is better science.

Perifollicular Fibrosis and Inflammation in AGA

Collagenous sheath thickening and inflammatory infiltrates are documented around miniaturizing follicles in androgenetic alopecia

Active family
AGA Pathology
Source assessment
Strong Evidence
Experimental detail
Multiple histological studies (Jaworsky 1992, Whiting 1993, Umar 2026) demonstrate perifollicular inflammation and fibrotic remodeling in AGA scalps. Contemporary reviews frame fibrosis as a plausible modifiable axis, though whether it is a primary cause or secondary consequence of miniaturization remains debated.

Scope of the evidence

Causal direction is uncertain — fibrosis may be consequence rather than driver. However, targeting this axis remains a rational strategy given the histological evidence.

GHK Modulates Over 4,000 Human Genes via Connectivity Map

Connectivity Map data indicates GHK at 1 µM modulates over 4,000 human genes, including ECM synthesis, growth factors (VEGF, bFGF), anti-inflammatory pathways, and stem cell maintenance

Active family
GHK Biology
Source assessment
Moderate Evidence
Experimental detail
Pickart & Margolina (2018) analyzed Connectivity Map data showing GHK modulates 2,687 upregulated and 1,513 downregulated genes at ≥50% change. Campbell et al. (2012) independently validated CMap predictions, confirming GHK at 10 nM reverses disease gene signatures in primary human fibroblasts.

Scope of the evidence

CMap data comprises only three expression profiles from two cancer cell lines (PC3, MCF7), making it statistically underpowered by modern standards. Independent validation (Campbell 2012) substantially bolsters confidence but used lung fibroblasts, not follicular cells.

Tripeptide-Copper Complex Stimulates Hair Follicle Growth Ex Vivo

AHK-Cu (Ala-His-Lys-Cu, a GHK analog) stimulates human hair follicle elongation and dermal papilla cell proliferation while suppressing apoptosis

Active family
Peptide Hair Evidence
Source assessment
Moderate Evidence
Experimental detail
Pyo et al. (2007) demonstrated that AHK-Cu at 10⁻¹² to 10⁻⁹ M stimulated ex vivo human hair shaft elongation, increased DPC proliferation, elevated Bcl-2/Bax ratio, and reduced cleaved caspase-3 by 42.7% and PARP by 77.5%.

Scope of the evidence

This study used AHK-Cu (Ala-His-Lys), not GHK-Cu (Gly-His-Lys). While structurally related, they are distinct peptides. Marketing literature that cites this study as evidence for GHK-Cu or Biotinoyl Tripeptide-1 is technically inaccurate.

Sederma/BIO-EC (unpublished supplier data)

Biotinoyl Tripeptide-1 Stimulates Ex Vivo Follicular Growth

Biotinoyl Tripeptide-1 at 2 ppm increased hair follicle growth by 58% ex vivo, comparable to minoxidil; at 5 ppm, growth was 121% greater than controls

Active family
Peptide Hair Evidence
Source assessment
Limited Evidence
Experimental detail
Sederma’s contract research (BIO-EC) cultured human hair follicle explants for 14 days with Biotinoyl Tripeptide-1 alone. Ki67 immunostaining confirmed maintained keratinocyte proliferation. Immunofluorescence showed the peptide preserved basement membrane proteins (laminin-5, collagen IV).

Scope of the evidence

Supplier-generated data that has not been published in a peer-reviewed journal or independently replicated. The ex vivo culture model does not account for the complex hormonal, vascular, and immune environment of the human scalp.

GHK + 5-ALA RCT Shows Hair Count Increase in AGA

The only controlled clinical trial for a GHK-containing formulation showed +52 to +72 hairs vs +10 for placebo over 6 months in 45 men with AGA

Active family
Peptide Hair Evidence
Source assessment
Moderate Evidence
Experimental detail
Lee et al. (2016) conducted a double-blind, placebo-controlled RCT using ALAVAX (5-aminolevulinic acid + free GHK without copper) in 45 men with androgenetic alopecia over 6 months. Zero adverse events reported.

Scope of the evidence

GHK was combined with 5-ALA; the individual contribution of GHK cannot be isolated. The study used free GHK (not GHK-Cu or Biotinoyl Tripeptide-1), so results may not directly apply to other molecular forms.

CIR Expert Panel: Tripeptide-1 Safe in Cosmetics

The independent CIR Expert Panel concluded that Tripeptide-1, Copper Tripeptide-1, and related derivatives are safe in cosmetics at current use concentrations

Active family
Safety
Source assessment
Strong Evidence
Experimental detail
Johnson et al. (2018) reviewed acute oral toxicity (LD₅₀ >2,000 mg/kg), negative RIPT, minimal ocular irritation, and nonmutagenic Ames test results. Ong et al. (2016) showed GHK-Cu is non-cytotoxic and non-irritating while equivalent free copper salts induced toxicity markers.

Scope of the evidence

The CIR assessment covers the peptide class broadly; it does not specifically evaluate the four myristoylated lipopeptides (Pentapeptide-17, Hexapeptide-16, Tetrapeptide-12) as individual ingredients.

Latanoprost RCT for Scalp Androgenetic Alopecia

Latanoprost 0.1% applied topically to AGA-affected scalp increased hair density versus placebo over 24 weeks — the first RCT evidence for a prostaglandin analog in scalp hair enhancement

Active family
Prostaglandin Clinical
Source assessment
Moderate Evidence
Experimental detail
Blume-Peytavi et al. (2012) conducted a randomized, double-blind, placebo-controlled pilot study. Latanoprost-treated areas showed significant increases in both terminal and vellus hair density compared to placebo-treated areas on the same scalp.

Scope of the evidence

Small pilot study with limited sample size. Scalp-specific safety and long-term outcomes were not fully characterized. Regulatory classification of a PG analog for scalp use may differ from ophthalmic/cosmetic eyelash applications.

Formulation guide

Formulation guide

Practical guidance for formulating with cosmetic peptides. These are starting points — formulation-specific testing is always recommended.

Cosmetic Peptide Use Levels

Recommended concentrations for the four cosmetic peptides

  • Biotinoyl Tripeptide-1: 1–50 ppm in finished formulation (scalp, lash/brow serums)
  • Myristoyl Pentapeptide-17: 1–10 ppm (lash/brow serums, scalp serums)
  • Myristoyl Hexapeptide-16: 1–20 ppm (designed as companion to Pentapeptide-17)
  • Myristoyl Tetrapeptide-12: 1–20 ppm (scalp serums)

Peptide Handling & Solubility

Practical guidance for working with cosmetic peptides

  • All four peptides are water-soluble — add to the aqueous phase
  • Myristoyl lipopeptides may require gentle warming (40°C) for complete dissolution
  • Store peptide raw materials at 2–8°C; protect from moisture
  • Peptides are compatible with standard cosmetic preservation systems at typical use levels
  • pH stability range: 4.5–7.0 for peptide-containing formulations

Peptide Stability Considerations

Key stability factors specific to peptide actives

  • Peptides are susceptible to proteolytic degradation in formulations containing botanical extracts with protease activity
  • Myristoyl (C14 fatty acid) conjugation improves lipopeptide stability relative to unconjugated peptides
  • Avoid prolonged exposure to temperatures above 50°C during manufacturing
  • Monitor pH drift in accelerated stability studies — peptide bonds can hydrolyze at extreme pH
  • No published long-term stability data for these specific peptide sequences — formulation-specific ICH stability testing is recommended

Regulatory context

Non-prostaglandin positioning

Mironova offers prostaglandin analogs and cosmetic peptide alternatives. For formulators who need prostaglandin-free positioning due to regulatory requirements, brand strategy, or market access, peptide ingredients provide a distinct cosmetic pathway.

European Union

Increasing PG restrictions [A1]

  • SCCS/1680/25 (Feb 2026) concludes prostaglandin analogs MDN, IPCP, and DDDE “cannot be considered safe” in cosmetic products intended to promote eyelash/eyebrow growth.
  • Products claiming to “stimulate hair growth” are assessed case-by-case for cosmetic vs medicinal classification.

Canada

PGs prohibited in cosmetics [A2]

  • Health Canada’s Cosmetic Ingredient Hotlist prohibits prostaglandins, their salts, derivatives and analogues in cosmetic products.
  • Brands selling in Canada increasingly specify “prostaglandin-free” formulations.

United States

Claim-driven classification [A3]

  • FDA classification depends on intended use, not ingredient identity. “Hair restoration” = medical claim. “Fuller-looking hair” = cosmetic claim.
  • 21 CFR 310.527 addresses OTC hair grower/hair loss prevention claims — these lack GRASE status.
  • MoCRA (2022) adds cosmetic safety substantiation requirements but does not change the medical/cosmetic claim boundary.
Prostaglandin analogs

Claims language

Claims language guide

Cosmetic claims must focus on appearance and maintenance, not treatment or disease modification.

Peptide claims discipline

Peptide claims discipline

MoCRA (2022) requires adequate substantiation for cosmetic product safety and claims. Mironova grades each peptide’s evidence level transparently. “Supports the appearance of” is the appropriate claim framework for all four peptides.

Evidence grades describe the available source basis, not regulatory approval.
PeptideStrongest EvidenceGradeKey Limitation
Biotinoyl Tripeptide-1Ex vivo follicle growth (+58–121%), laminin-5/collagen IV preservation, follicular localizationDEMONSTRATED (supplier)No independent peer-reviewed replication; clinical data is for Procapil complex only
Myristoyl Pentapeptide-17In vitro keratin gene upregulation (KRT3, KRT19, lumican), supplier eyelash studySUPPLIER DATAHair loss study (n=24) did not reach statistical significance; KRT31/KRT35 claims are unsupported
Myristoyl Hexapeptide-16Designed as companion to Pentapeptide-17; cationic lipopeptide class reasoningCLASS EVIDENCENo peptide-specific efficacy data published or available; thinnest evidence base of all four
Myristoyl Tetrapeptide-12Myristoyl tetrapeptide class shows ECM modulation via TGF-β/SMAD signalingCLASS EVIDENCEPublished data is for different peptide sequences (mAAPV, mGLFW), not this specific KAKA sequence

Grades: DEMONSTRATED = peptide-specific data exists (may be supplier-only). CLASS EVIDENCE = data from related compounds or peptide class. HYPOTHETICAL = mechanistically plausible, no direct data. See product pages for full evidence detail.

Product specifications

Product quality & specifications

Compound-specific specifications, formulation properties and handling information.

Catalog specifications. Measured batch results belong on the lot-specific CoA.
PropertyBiotinoyl Tripeptide-1 (Biotin-GHK)Myristoyl Pentapeptide-17 (Myr-PP17)Myristoyl Hexapeptide-16 (Myr-HP16)Myristoyl Tetrapeptide-12 (Myr-TP12)
Active BaseBiotinyl-Gly-His-LysMyr-KLAKK-NH₂Myr-LKKALKMyr-KAKA (patented sequence)
CAS (Free Base)299157-54-3959610-30-1959610-54-9Proprietary
INCI NameBIOTINOYL TRIPEPTIDE-1MYRISTOYL PENTAPEPTIDE-17MYRISTOYL HEXAPEPTIDE-16MYRISTOYL TETRAPEPTIDE-12
Purity≥95% (HPLC)≥95% (HPLC)≥95% (HPLC)≥95% (HPLC)
AppearanceWhite to off-white lyophilized powderWhite to off-white lyophilized powderWhite to off-white lyophilized powderWhite to off-white lyophilized powder
SolubilityFreely soluble in waterSoluble in water and aqueous buffersSoluble in water; slight warming may aid dissolutionSoluble in water and aqueous buffers
pH (1.5% aq.)4.5–7.5 (aqueous solution)5.0–7.0 (aqueous solution)5.0–7.0 (aqueous solution)4.5–7.5 (aqueous solution)
Use Level1–50 ppm (w/w)1–10 ppm (w/w)1–20 ppm (w/w)1–20 ppm (w/w)
Storage−20°C, protect from moisture and light−20°C, protect from moisture and light−20°C, protect from moisture and light−20°C, protect from moisture and light
Primary MechanismGHK-class matrikine signaling (ECM remodeling in dermal papilla)Keratin gene upregulation in follicular keratinocytes (supplier in vitro data)Lipopeptide companion active for eyelash/brow and scalp serums (supplier data)Dermal papilla ECM remodeling (collagen IV, fibronectin upregulation; supplier data)
AvailabilityMade to OrderMade to OrderMade to OrderMade to Order
Product pageBiotinoyl Tripeptide-1 Product PageMyristoyl Pentapeptide-17 Product PageMyristoyl Hexapeptide-16 Product PageMyristoyl Tetrapeptide-12 Product Page

Manufacturing

Manufacturing & quality

US-Based Manufacturing

Produced at our Fairfield, NJ facility with full supply chain transparency.

Certificate of Analysis

Every batch ships with CoA including HPLC purity, identity confirmation, and moisture content.

Batch Consistency

Stoichiometry confirmed by HPLC and elemental analysis for each batch.

Technical inquiry

Evaluate our hair enhancement actives

Request samples of cosmetic peptides, prostaglandin analogs, or a tailored combination for your project.

Sample Quantities

5–25 g evaluation samples shipped within 1–2 weeks, with development and commercial scale available on request

Technical Documentation

CoA, formulation guidance, and use-level recommendations included with every sample shipment

Technical Support

Direct access to our chemistry team for formulation optimization, pH adjustment, and compatibility testing

Products (select one or more) *

Cosmetic Peptides

Prostaglandin Analogs

Quantity

We typically respond within 1–2 business days with sample availability and technical documentation.

References

Literature & sources

Technical claims retain their source context and limitations. DOIs are supplied where available.

  1. EU SCCS Opinion SCCS/1680/25 on Prostaglandin Analogues in Cosmetics

    SCCS concludes that prostaglandin analogues MDN, isopropyl cloprostenate, and DDDE cannot be considered safe in cosmetic products intended to promote eyelash/eyebrow growth. Cites reproductive/developmental toxicity data gaps.

  2. Health Canada Cosmetic Ingredient Hotlist — Prostaglandins

    Prostaglandins, their salts, derivatives and analogues are listed as prohibited in cosmetic products in Canada, creating market demand for non-prostaglandin alternatives.

  3. FDA Cosmetic Classification Guidance

    Claims to “restore hair growth” or “treat hair loss” are restricted medical claims under US FDA guidance. Cosmetic claims must focus on appearance (e.g., “fuller-looking hair”). MoCRA (2022) adds oversight but does not change the claim boundary.

  4. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    Pickart L, Margolina A

    Comprehensive review demonstrating that GHK modulates expression of over 4,000 human genes based on Connectivity Map data, including ECM remodeling, anti-inflammatory, and stem cell-related pathways relevant to follicular biology.

    DOI 10.3390/ijms19071987
  5. A Gene Expression Signature of Emphysema-Related Lung Destruction and Its Reversal by the Tripeptide GHK

    Campbell JD, McDonough JE, Zeskind JE, et al.

    Independent multi-institutional validation of GHK’s Connectivity Map gene expression predictions. Confirmed that GHK at 10 nM reverses disease-associated gene expression patterns in primary human fibroblasts, substantially bolstering confidence in CMap-derived claims.

    DOI 10.1186/gm368
  6. The Effect of Tripeptide-Copper Complex on Human Hair Growth in vitro

    Pyo HK, Yoo HG, Won CH, et al.

    Ex vivo study demonstrating that a tripeptide-copper complex (AHK-Cu, not GHK-Cu) stimulates human hair follicle elongation and dermal papilla cell proliferation while suppressing apoptosis (42.7% caspase-3 reduction, 77.5% PARP reduction). Note: frequently miscited as GHK-Cu evidence.

  7. Efficacy and Safety of Topical 5-Aminolevulinic Acid Photodynamic Therapy and GHK Peptide for Androgenetic Alopecia

    Lee WJ, Kim KH, et al.

    Double-blind, placebo-controlled RCT in 45 men over 6 months. Hair counts increased by +52 to +72 hairs in treatment groups versus +10 for placebo (p<0.05). Limitation: GHK was combined with 5-ALA, so its individual contribution cannot be isolated.

    DOI 10.5021/ad.2016.28.4.438
  8. Thermodynamically Stable Ionic Liquid Microemulsions Pioneer Pathways for Topical Delivery and Peptide Application

    Liu T, et al.

    GHK-Cu delivered via ionic liquid microemulsion induced anagen in mice within 6 days versus 9 days for 5% minoxidil, with confirmed upregulation of VEGF, HGF, and Wnt/β-catenin signaling.

  9. Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds

    Ong KL, et al.

    GHK-Cu showed no cytotoxicity and no elevation of irritancy biomarkers in HaCaT keratinocytes, while equivalent concentrations of free copper salts induced both cytotoxicity and irritancy markers — demonstrating that GHK complexation effectively quenches copper’s redox toxicity.

  10. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics

    Johnson W, Bergfeld WF, Belsito DV, et al.

    CIR Expert Panel safety assessment concluding that Tripeptide-1, Copper Tripeptide-1, and related derivatives are “safe in cosmetics in the present practices of use and concentration.” Supporting data included negative RIPT, Ames test, and minimal irritation.

  11. Eyelash Growth in Subjects Treated with Bimatoprost: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study

    Smith S, Fagien S, Whitcup SM, et al.

    Phase III trial (n=278) demonstrating bimatoprost 0.03% applied to the upper eyelid margin significantly increases eyelash length, thickness, and darkness versus vehicle (78.1% vs 18.4% responders at 16 weeks, P<.0001), forming the basis for FDA approval of Latisse.

    DOI 10.1016/j.jaad.2011.06.005
  12. Identification and Pharmacological Characterization of the Prostaglandin FP Receptor and FP Receptor Variant Complexes

    Liang Y, Woodward DF, Guzman VM, Li C, Scott DF, Wang JW, Wheeler LA, Garst ME, Landsverk K, Sachs G, Bhatt K, Krauss AHP

    Identifies and characterizes the prostaglandin FP receptor and FP receptor variant complexes, establishing the pharmacological basis for how prostaglandin F2α analogs mediate biological effects including hair follicle stimulation.

    DOI 10.1038/bjp.2008.142
  13. A Randomized Double-Blind Placebo-Controlled Pilot Study to Assess the Efficacy of a 24-Week Topical Treatment by Latanoprost 0.1% on Hair Growth and Pigmentation in Healthy Volunteers with Androgenetic Alopecia

    Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N

    Randomized, double-blind, placebo-controlled pilot study (n=16) showing latanoprost 0.1% applied topically to AGA-affected scalp significantly increased hair density versus baseline (P<.001) and placebo (P=.0004) over 24 weeks, providing early RCT evidence for a prostaglandin analog in scalp hair enhancement.

    DOI 10.1016/j.jaad.2011.05.026
  14. A Cross-Sectional Survey of the Association between Bilateral Topical Prostaglandin Analogue Use and Ocular Adnexal Features

    Shah M, Lee G, Lefebvre DR, et al.

    Cross-sectional survey (n=343) documenting periorbital adverse effects of topical prostaglandin analogs including 2.3-fold increased risk of dermatochalasis involution, 2.5-fold increased periorbital fat loss, and 4.0-fold increased upper lid ptosis — establishing the safety profile that drives regulatory scrutiny and demand for non-PG alternatives.

    DOI 10.1371/journal.pone.0061638

FAQ

Frequently asked questions.

What active families does Mironova offer for hair enhancement?

Mironova offers two complementary families: cosmetic peptides (Biotinoyl Tripeptide-1 and three Myristoyl lipopeptides) for scalp, lash, and brow formulations, and prostaglandin analogs (bimatoprost, latanoprost, travoprost, and others) for pharmaceutical and cosmetic hair applications.

How do peptide actives differ from prostaglandin analogs?

Peptides target ECM remodeling and keratin gene expression, while prostaglandin analogs act via FP receptor agonism to prolong anagen phase. The appropriate family depends on the intended application, claim language, and regulatory context.

Are the cosmetic peptide actives water-soluble?

Yes. The cosmetic peptides are water-soluble and suitable for aqueous serums, scalp tonics, and shampoo formulations. Myristoyl lipopeptides may require gentle warming (40°C) for complete dissolution.

What is the recommended use level?

Cosmetic peptides are typically used at 1–50 ppm depending on the specific peptide. Prostaglandin analog concentration depends on the specific compound, intended use, and regulatory jurisdiction.

What is the difference between GHK-Cu and Biotinoyl Tripeptide-1?

Both contain the GHK (Gly-His-Lys) peptide sequence, which is an established matrikine with ECM-modulating properties. GHK-Cu complexes GHK with copper, while Biotinoyl Tripeptide-1 conjugates GHK with biotin. The biotin conjugation avoids the formulation complexity and stability challenges of copper coordination, and supplier ex vivo data shows follicular localization and ECM preservation specific to the biotin-GHK conjugate.

What evidence supports the Myristoyl lipopeptide series for lash/brow?

Myristoyl Pentapeptide-17 has supplier in vitro data (keratin gene upregulation in skin models) and small-scale eyelash studies. Hexapeptide-16 is designed as a companion active with class-level lipopeptide evidence. Both are used in commercial lash serums. Independent peer-reviewed clinical trials for these specific peptides as monotherapy have not been published. Mironova provides transparent evidence grading for each peptide.

What are the storage and handling requirements for peptide actives?

Peptide raw materials should be stored at 2–8°C and protected from moisture. In finished formulations, peptides are stable within pH 4.5–7.0 at typical cosmetic storage conditions. Avoid formulations containing proteolytic enzymes from botanical extracts. Long-term stability testing in your specific formulation is recommended.

Related resources

Technical data and application guidance.

Product Catalog

View specifications, CoA, and order evaluation samples.

Read resource